The science of rheumatoid arthritis: A prelude

Arthritis Research and Therapy

Volumn 7, Issue SUPPL. 2, 2005, Pages

  Smolen, Josef S ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; ATLIZUMAB; AUTOANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; HELPER FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FC FUSION PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; JOINT DESTRUCTION; LONG TERM CARE; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; PATHOGENESIS; PROGNOSIS; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE ACTIVATION;

EID: 19544370591     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1720     Document Type: Editorial

References (24)

1. Feldmann M, Maini RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001, 19:163-196.
2. Gravallese EM: Bone destruction in arthritis. Ann Rheum Dis 2002, Suppl 2:ii84-ii86.
3. Scott DL, Symmons DP, Coulton BL, Popert AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987, 1:1108-1111.
4. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
5. Aho K, von Essen R, Kurki P, Palosuo T, Heliovaara M: Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993, 20: 1278-1281.
6. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999, 26:705-722.
7. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, et al.: How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002, 47:215-218.
8. Weinblatt ME: Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003, Suppl ii:ii94-ii96.
9. Nell V, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:906-914.
10. Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488.
11. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS: Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003, Suppl 31:S178-S185.
12. Weinblatt ME: Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 1995, Suppl 2:43-48.
13. Elliott MJ, Maini RN, Feldmann M, Kaden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
14. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K: The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
15. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kaden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
16. Smolen JS, Han C, Bala M, Maini R, Kalden J, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE: Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed sub-analysis of the ATTRACT trial. Arthritis Rheum 2005, in press.
17. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
18. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769.
19. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
20. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Berke A, Gal A, Kunaver M, Zenz P, Smolen JS: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:202-213.
21. van der Lubbe PA, Dijkmans BS, Markusse H, Nassander U, Breedveld FC: A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995, 38:1097-1106.
22. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
23. Burger D, Dayer JM: The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res 2002, Suppl 3:S169-S176.
24. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.